Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 5/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | ICMT | O60725 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | MMP9 | P14780 | 2/20 | 0.37 |
| ▸ | MMP8 | P22894 | 2/20 | 0.37 |
| ▸ | MMP13 | P45452 | 2/20 | 0.37 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.37 |
| ▸ | GBA1 | P04062 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12640254 | 0.89 | HDAC1 (0.46) | HDAC1CSNK2A1EPHX2ICMTGGPS1 | |
| SCHEMBL13437065 | 0.88 | FOLH1 (0.46) | HDAC1CSNK2A1FOLH1EPHX2MMP2 | |
| SCHEMBL19303294 | 0.86 | FOLH1 (0.47) | HDAC1CSNK2A1FOLH1EPHX2MMP2 | |
| SCHEMBL21626004 | 0.86 | POLB (0.47) | HDAC1CSNK2A1EPHX2ICMTGBA1 | |
| SCHEMBL16234065 | 0.82 | CSNK2A1 (0.40) | HDAC1CSNK2A1EPHX2ICMTGGPS1 | |
| SCHEMBL19296370 | 0.80 | FOLH1 (0.47) | HDAC1CSNK2A1FOLH1EPHX2MMP2 | |
| SCHEMBL19303332 | 0.80 | FOLH1 (0.47) | HDAC1CSNK2A1FOLH1EPHX2MMP2 | |
| SCHEMBL17776274 | 0.79 | EPHX2 (0.46) | HDAC1CSNK2A1FOLH1EPHX2GBA1 | |
| SCHEMBL17490608 | 0.79 | EPHX2 (0.46) | HDAC1CSNK2A1EPHX2GGPS1GBA1 | |
| SCHEMBL17776313 | 0.79 | EPHX2 (0.52) | HDAC1FOLH1EPHX2GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680260-B2 | 18F-labeled azide compound, reagent for 18F-labeling and method for 18F-labeling of alkyne compound using same | RIKEN (JP) | 2014-03-25 | — | — | US | disclosed |
| US-20120101266-A1 | 18F-LABELED AZIDE COMPOUND, REAGENT FOR 18F-LABELING AND METHOD FOR 18F-LABELING OF ALKYNE COMPOUND USING SAME | RIKEN (JP) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101266-A1 | 18F-LABELED AZIDE COMPOUND, REAGENT FOR 18F-LABELING AND METHOD FOR 18F-LABELING OF ALKYNE COMPOUND USING SAME | UMPS, APOBEC3G, FPR1 | HDAC1 3693/4885CSNK2A1 4646/4885FOLH1 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.